140 related articles for article (PubMed ID: 34938660)
1. A Three lncRNA Set: AC009975.1, POTEH-AS1 and AL390243.1 as Nodal Efficacy Biomarker of Neoadjuvant Therapy for HER-2 Positive Breast Cancer.
Bi Z; Qiu PF; Zhang Y; Song XG; Chen P; Xie L; Wang YS; Song XR
Front Oncol; 2021; 11():779140. PubMed ID: 34938660
[TBL] [Abstract][Full Text] [Related]
2. Laboratory indicators predict axillary nodal pathologic complete response after neoadjuvant therapy in breast cancer.
Chen P; Zhao T; Bi Z; Zhang ZP; Xie L; Liu YB; Song XG; Song XR; Wang CJ; Wang YS
Future Oncol; 2021 Jul; 17(19):2449-2460. PubMed ID: 33878939
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety analysis of paclitaxel, docetaxel and liposomal paclitaxel after neoadjuvant therapy in breast cancer.
Bi Z; Chen P; Liu YB; Zhao T; Sun X; Song XR; Wang YS
Breast Cancer Res Treat; 2020 Nov; 184(2):397-405. PubMed ID: 32776291
[TBL] [Abstract][Full Text] [Related]
4. Serum LncRNA-ATB and FAM83H-AS1 as diagnostic/prognostic non-invasive biomarkers for breast cancer.
El-Ashmawy NE; Hussien FZ; El-Feky OA; Hamouda SM; Al-Ashmawy GM
Life Sci; 2020 Oct; 259():118193. PubMed ID: 32763293
[TBL] [Abstract][Full Text] [Related]
5. Candidates of Genomic Tests in HR+/HER2- Breast Cancer Patients With 1-2 Positive Sentinel Lymph Node Without Axillary Lymph Node Dissection: Analysis From Multicentric Cohorts.
Bi Z; Chen JJ; Liu PC; Chen P; Wang WL; Liu YB; Wang CJ; Qiu PF; Lv Q; Wu J; Wang YS
Front Oncol; 2021; 11():722325. PubMed ID: 34422668
[TBL] [Abstract][Full Text] [Related]
6. Predictive factors of pathologically node-negative disease for HER2 positive and triple-negative breast cancer after neoadjuvant therapy.
Shi Z; Wang X; Qiu P; Liu Y; Zhao T; Sun X; Chen P; Wang C; Zhang Z; Cong B; Wang Y
Gland Surg; 2021 Jan; 10(1):166-174. PubMed ID: 33633973
[TBL] [Abstract][Full Text] [Related]
7. A nine-lncRNA signature predicts distant relapse-free survival of HER2-negative breast cancer patients receiving taxane and anthracycline-based neoadjuvant chemotherapy.
Sun M; Liu X; Xia L; Chen Y; Kuang L; Gu X; Li T
Biochem Pharmacol; 2021 Jul; 189():114285. PubMed ID: 33069665
[TBL] [Abstract][Full Text] [Related]
8. Tumor-infiltrating lymphocytes benefit prediction of axillary pathologic response and prognostication of event-free survival in HER2-positive and biopsy-proven node-positive breast cancer treated with neoadjuvant therapy.
Liu S; Zeng S; Xia L; Yu M; Zhang X; Yang H; Ji J; Dong H; Zhang J; Zhang P
Breast Cancer Res Treat; 2021 Feb; 185(3):629-638. PubMed ID: 33165709
[TBL] [Abstract][Full Text] [Related]
9. Profiling of specific long non-coding RNA signatures identifies ST8SIA6-AS1 AS a novel target for breast cancer.
Chen Z; Huang J; Feng Y; Li Z; Jiang Y
J Gene Med; 2021 Feb; 23(2):e3286. PubMed ID: 33037712
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive analysis of novel three-long noncoding RNA signatures as a diagnostic and prognostic biomarkers of human triple-negative breast cancer.
Fan CN; Ma L; Liu N
J Cell Biochem; 2019 Mar; 120(3):3185-3196. PubMed ID: 30203490
[TBL] [Abstract][Full Text] [Related]
11. Combined identification of long non-coding RNA XIST and HIF1A-AS1 in serum as an effective screening for non-small cell lung cancer.
Tantai J; Hu D; Yang Y; Geng J
Int J Clin Exp Pathol; 2015; 8(7):7887-95. PubMed ID: 26339353
[TBL] [Abstract][Full Text] [Related]
12. Nomogram to Predict Tumor-Infiltrating Lymphocytes in Breast Cancer Patients.
Feng J; Li J; Huang X; Yi J; Wu H; Zou X; Zhong W; Wang X
Front Mol Biosci; 2021; 8():761163. PubMed ID: 34901155
[No Abstract] [Full Text] [Related]
13. Long Non-Coding RNAs Expression in Breast Cancer: CBR3-AS1 LncRNA as a Sensitive Biomarker.
Torkashvand S; Basi A; Ajdarkosh H; Rakhshani N; Nafisi N; Mowla SJ; Moghadas A; Mohammadipour M; Karbalaie Niya MH
Asian Pac J Cancer Prev; 2021 Sep; 22(9):2897-2902. PubMed ID: 34582659
[TBL] [Abstract][Full Text] [Related]
14. Predictive value of lncRNA LOC100505851 in breast cancer in the neoadjuvant setting.
Sha R; Wu Z; Xu Y; Sheng X; Wang Y; Yuan C; Peng J; Xu S; Zhou L; Lin Y; Yin W; Lu J
Gland Surg; 2021 Jun; 10(6):1899-1909. PubMed ID: 34268074
[TBL] [Abstract][Full Text] [Related]
15. Study on expression of lncRNA RGMB-AS1 and repulsive guidance molecule b in non-small cell lung cancer.
Li P; Li J; Yang R; Zhang F; Wang H; Chu H; Lu Y; Dun S; Wang Y; Zang W; Du Y; Chen X; Zhao G; Zhang G
Diagn Pathol; 2015 Jun; 10():63. PubMed ID: 26055877
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of the long noncoding RNAs DSCAM-AS1 and MANCR is a potential diagnostic marker for breast carcinoma.
Tahmouresi F; Razmara E; Pakravan K; Mossahebi-Mohammadi M; Rouhollah F; Montazeri M; Sarrafzadeh A; Fahimi H; Babashah S
Biotechnol Appl Biochem; 2021 Dec; 68(6):1250-1256. PubMed ID: 33012018
[TBL] [Abstract][Full Text] [Related]
17. Identification of lncRNA
Yang F; Lv SX; Lv L; Liu YH; Dong SY; Yao ZH; Dai XX; Zhang XH; Wang OC
Onco Targets Ther; 2016; 9():7039-7045. PubMed ID: 27895496
[TBL] [Abstract][Full Text] [Related]
18. Identification of MFI2-AS1, a Novel Pivotal lncRNA for Prognosis of Stage III/IV Colorectal Cancer.
Luo R; Song J; Zhang W; Ran L
Dig Dis Sci; 2020 Dec; 65(12):3538-3550. PubMed ID: 31960204
[TBL] [Abstract][Full Text] [Related]
19. Expression analysis of vimentin and the related lncRNA network in breast cancer.
Mohebi M; Ghafouri-Fard S; Modarressi MH; Dashti S; Zekri A; Kholghi-Oskooei V; Taheri M
Exp Mol Pathol; 2020 Aug; 115():104439. PubMed ID: 32283061
[TBL] [Abstract][Full Text] [Related]
20. Circulating Tumor DNA as a Predictive Marker of Recurrence for Patients With Stage II-III Breast Cancer Treated With Neoadjuvant Therapy.
Lin PH; Wang MY; Lo C; Tsai LW; Yen TC; Huang TY; Huang WC; Yang K; Chen CK; Fan SC; Kuo SH; Huang CS
Front Oncol; 2021; 11():736769. PubMed ID: 34868925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
